NCT00104858 - Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

March 30, 2018

Study Completion Date

March 30, 2018

Conditions

Chronic Lymphocytic LeukemiaProlymphocytic LeukemiaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic LeukemiaStage III Chronic Lymphocytic LeukemiaStage III Small Lymphocytic LymphomaStage IV Chronic Lymphocytic LeukemiaStage IV Small Lymphocytic LymphomaT-Cell Large Granular Lymphocyte Leukemia

Interventions

PROCEDURE

Allogeneic Hematopoietic Stem Cell Transplantation

Undergo HSCT

DRUG

Cyclosporine

Given PO

DRUG

Fludarabine Phosphate

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Mycophenolate Mofetil

Given PO

PROCEDURE

Peripheral Blood Stem Cell Transplantation

Undergo HSCT

OTHER

Pharmacological Study

Correlative studies

BIOLOGICAL

Rituximab

Given IV

RADIATION

Total-Body Irradiation

Undergo TBI

Trial Locations (5)

2100

Rigshospitalet University Hospital, Copenhagen

10126

University of Torino, Torino

55905

Mayo Clinic, Rochester

98101

VA Puget Sound Health Care System, Seattle

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Fred Hutchinson Cancer Center

OTHER